Hintschich C, Feyh J, Beyer-Machule C, Riedel K, Ludwig K
Augenklinik, Ludwig-Maximilians-Universität, München, Germany.
Ger J Ophthalmol. 1993 Aug;2(4-5):212-7.
Photodynamic therapy (PDT) remains an experimental approach for the treatment of small, mainly superficial malignant tumors. When given intravenously, hematoporphyrin derivative (HpD) selectively photosensitizes tumor tissue. Activated by light of 630 nm wave-length, HpD leads to tumor necrosis. This paper presents the results of PDT to eyelid basal-cell carcinomas in 21 patients. All lesions primarily responded to the treatment and became necrotic. A generalized photosensitization lasting for more than 4 weeks was seen in all patients. In five patients, lid malformations due to scar formation were noted, being marked in three cases. Ten patients showed a recurrence of tumor after 3-12 months. At present, PDT has no advantage over well-established therapies for basal-cell carcinomas of the eyelid.
光动力疗法(PDT)仍然是一种用于治疗小型、主要为浅表性恶性肿瘤的实验性方法。静脉注射血卟啉衍生物(HpD)后,其可选择性地使肿瘤组织产生光致敏作用。在波长630nm的光激活下,HpD会导致肿瘤坏死。本文介绍了对21例眼睑基底细胞癌进行光动力疗法的结果。所有病变最初对治疗均有反应并发生坏死。所有患者均出现了持续超过4周的全身性光致敏现象。5例患者出现了因瘢痕形成导致的眼睑畸形,其中3例较为明显。10例患者在3 - 12个月后出现肿瘤复发。目前,对于眼睑基底细胞癌,光动力疗法相较于已成熟的治疗方法并无优势。